Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 03

247TiP - Addition of induction, concurrent and maintenance durvalumab to induction and concurrent chemoradiation vs induction and concurrent chemoradiation for previously untreated locoregionally advanced nasopharyngeal carcinoma: A phase II randomised-controlled trial

Date

03 Dec 2022

Session

Poster viewing 03

Topics

Cytotoxic Therapy;  Immunotherapy

Tumour Site

Head and Neck Cancers

Presenters

Victor Lee

Citation

Annals of Oncology (2022) 33 (suppl_9): S1521-S1529. 10.1016/annonc/annonc1128

Authors

V.H.F. Lee1, D.L.W. Kwong2, A.S.Y. Chan2, C.C. Tong2, R. Tsang3, C.K. Chung4

Author affiliations

  • 1 Department Of Clinical Oncology, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Nil - Hong Kong/HK
  • 2 Department Of Clinical Oncology, The University of Hong Kong - Queen Mary Hospital, Hong Kong/HK
  • 3 Department Of Otolaryngology, NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), 117596 - Singapore/SG
  • 4 Department Of Surgery, HKU - The University of Hong Kong, Hong Kong/HK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 247TiP

Background

Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia. Despite the most aggressive and devastating treatment with induction chemotherapy followed by concurrent chemoradiation, about 20-30% of patients with locoregionally advanced nasopharyngeal carcinoma (LANPC) suffer from relapse at 5 years. Addition of anti-PD(L)1 immune checkpoint inhibitor to this intensive radical treatment may help improve treatment outcomes and survival. We are conducting a phase II randomised-controlled trial on adding durvalumab as induction, concurrent and maintenance therapy to induction and concurrent chemoradiation compared to the same regimen without durvalumab for previously untreated LANPC patients.

Trial design

Patients with previously untreated LANPC (stage III to IVA disease except T3N0M0 based on TNM-8) are screened for study eligibility. After fulfilling all the study criteria, they will be randomised (in 1:1 ratio) to (a) experimental arm with a fixed dose durvalumab 1500mg intravenously administered every 4 weeks for 13 cycles and 3 cycles of induction chemotherapy with gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (100mg/m2 on day 1) every 3 weeks followed by concurrent chemoradiation with 3-weekly cisplatin (100mg/m2) infusion, or (b) control arm with the same regimen of induction chemotherapy and concurrent chemoradiation. The primary study end point is progression-free survival while the secondary end points are objective response, overall survival, safety profiles, change in tumour microenvironment before and after induction chemotherapy and concurrent chemoradiation (with or without durvalumab), and change in PD-L1 positive circulating tumour cells before and after induction chemotherapy and concurrent chemoradiation (with or without durvalumab). The study is still ongoing and expected to complete patient accrual (n=118) in end of December 2022.

Clinical trial identification

NCT04447612. Release date: 25 June 2020.

Legal entity responsible for the study

Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong.

Funding

AstraZeneca.

Disclosure

V.H.F. Lee: Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme, Amgen, Takeda, Bristol Myers Squibb, AstraZeneca, Roche; Financial Interests, Personal, Invited Speaker: Boston Scientific, Novartis, Merck Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.